Approval Delayed, But Janssen/Legend’s Cilta-Cel May Hit Market Just In Time

BMS/Bluebird’s Abecma Approved But Demand Exceeds Supply

 
• By Mandy Jackson
  
Close up of hourglass clock on a wooden floor
Time will tell if a three-month approval delay is meaningful for cilta-cel • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Manufacturing

More from Business